Monitor whether the post-split stock price sustains above $1.00 to avoid delisting; no fundamental catalyst for upside here. The clinical pipeline (seralutinib) remains the key value driver.
Price Chart
Executive Summary
Gossamer Bio announced a 1-for-80 reverse stock split effective September 10, 2026, to regain compliance with Nasdaq's minimum bid price requirement. Authorized common shares will be reduced from 4 billion to 50 million. This is a mechanical corporate action with no change to business fundamentals.
Key Facts
- 1-for-80 reverse stock split selected by board on September 9, 2026
- Effective September 10, 2026 at 11:59 p.m. ET; split-adjusted trading begins September 11, 2026
- Authorized common shares reduced from 4,000,000,000 to 50,000,000
- Total authorized capital stock reduced from 4,070,000,000 to 120,000,000
- Proportionate adjustments to convertible notes (5.00% 2027 and 7.50% 2030), warrants, prefunded warrants, and equity awards
- Fractional shares will be rounded up to the nearest whole share
- Reverse split intended to meet Nasdaq minimum bid price requirement for continued listing
Financial Impact
No direct financial impact; reverse stock split does not change aggregate market value or proportional ownership.
Risk Factors
- Reverse stock split may not result in sustained price above $1.00, risking delisting
- Potential increased volatility and negative sentiment from mechanical delisting risk signal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001728117-26-000091 |
| Exhibit: ex991revstocksplit.htm | 0001728117-26-000091 |
| Document: 0001728117-26-000091-index-headers.html | 0001728117-26-000091 |
| Document: 0001728117-26-000091-index.html | 0001728117-26-000091 |
| Document: 0001728117-26-000091.txt | 0001728117-26-000091 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | SC 13D/A | $9.31 | awaiting T+20 | — | $9.15 (+1.72%) |
Sep 28, 2026 28d ago | SC 13D/A | $11.58 | awaiting T+20 | — | $9.15 (+20.98%) |
Sep 22, 2026 4w ago | Institutional Cluster | $11.69 $9.58 | ▼ −18.05% | ▼ −17.49% | $9.15 (−21.73%) |
Sep 16, 2026 5w ago | 8-K | $11.94 $8.89 | ▼ −25.54% | ▼ −26.75% | $9.15 (−23.37%) |
Sep 11, 2026 6w ago | 8-K | $10.73 $9.31 | ▲ +13.23% | ▲ +15.10% | $9.15 (+14.73%) |
Sep 9, 2026 6w ago | 8-K | $0.1597 $0.1273 | ▼ −20.32% | ▼ −22.26% | $9.15 (+5629.49%) |
Aug 21, 2026 9w ago | 8-K | $0.1547 $0.1410 | ▲ +8.86% | ▲ +9.87% | $9.15 (−5814.67%) |
Aug 13, 2026 10w ago | 8-K | $0.1542 $0.1337 | ▼ −13.26% | ▼ −11.27% | $9.15 (+5833.85%) |
Jul 1, 2026 16w ago | 8-K | $0.1677 $0.1783 | ▼ −6.32% | ▼ −6.87% | $9.15 (−5356.17%) |
Jun 17, 2026 18w ago | 8-K | $0.1790 $0.1701 | ▲ +4.97% | ▲ +5.29% | $9.15 (−5011.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers